Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Apelian, R. G. [1 ]
Boyle, L. [2 ]
Hirman, J. [3 ]
Asher, D. [4 ]
机构：
[1] Huntington Headache & Neurol, Arcadia, CA USA
[2] Lundbeck LLC, Deerfield, IL USA
[3] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[4] Lundbeck LLC, Deerfield, IL USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-181
引用
收藏
页码：151 / 152
页数：2
相关论文
共 50 条
  • [1] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, Rami
    Boyle, Lee
    Hirman, Joe
    Asher, Divya
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [2] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Rami Apelian
    Lee Boyle
    Joe Hirman
    Divya Asher
    The Journal of Headache and Pain, 2022, 23
  • [3] Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    HEADACHE, 2021, 61 : 123 - 123
  • [4] Efficacy and Safety of Eptinezumab in Patients With Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 77 - 77
  • [5] Efficacy and Safety of Eptinezumab in Patients With Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 51 - 51
  • [6] Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
    Ashina, Messoud
    McAllister, Peter
    Cady, Roger
    Hirman, Joe
    Ettrup, Anders
    CEPHALALGIA, 2022, 42 (08) : 696 - 704
  • [7] Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
    Martin, V.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 105 - 106
  • [8] Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
    Martin, V.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 157 - 157
  • [9] Eptinezumab for migraine prevention in patients 50 years or older: A subgroup analysis of PROMISE-1 and PROMISE-2
    Martin, V. T.
    Tassorelli, C.
    Ettrup, A.
    Hirman, J.
    Cady, R.
    HEADACHE, 2021, 61 : 125 - 126
  • [10] Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
    Martin, V.
    Nagy, A. J.
    Janelidze, M.
    Giorgadze, G.
    Hirman, J.
    Cady, R.
    Mehta, L.
    Buse, D. C.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 17 - 17
12345